Smolensk State Medical Academy   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Smolensk Russian Federation (1918)

Organization Overview

First Clinical Trial
2005
NCT00415038
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Addiction Treatment Center, Clinical Facility of Smolensk State Medical Academy | Department of Internal Medicine, Postgraduate Education Faculty Smolensk State medical Academy - Smolensk (Russia) | Head of Department and Professor, Anaesthesia, PGIMER, Chandigarh | Smolensk State Medical Academy, Smolensk, Russia

Active Ingredients

Drugs in Phase 4 Trials (1)

torsemide (demadex) (1 trial)

Drugs in Phase 3 Trials (3)

interferon alpha-2b (Intron-A) (1 trial)

naltrexone (revia) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Phase 2 Trials (1)

rostafuroxin (1 trial)

Drugs in Other Trials (2)

methylprednisolone (medrol) (1 trial)

platelet-rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Essential Hypertension (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hypertension (Phase 4)

Opioid-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7